Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59,954 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Clear all
Terminated Phase 1 Interventional

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

NCT05065047
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 3, 2026, 2:58 AM EDT
Available No phase listed Expanded access

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

NCT06956547
View directory record Official record
Conditions
Lymphopenia
Interventions
nogapendekin-alfa inbakicept
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Bioanalytical Assays for Tebipenem

NCT05856747
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TBP-PI-HBr
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly

NCT00298558
View directory record Official record
Conditions
Aging, Healthy
Interventions
Cognitive Training
Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
65 Years and older
Enrollment
2,832 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 3 Interventional

Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome

NCT00190658
View directory record Official record
Conditions
Failure to Thrive
Interventions
Somatropin (rDNA origin) for injection
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Sep 3, 2026, 2:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

NCT04108858
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Copanlisib, Pertuzumab, Trastuzumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01280058
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Wild-type Reovirus
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

NCT02875548
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 3, 2026, 2:58 AM EDT
Terminated Phase 3 Interventional

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

NCT00396448
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598 Treatment B, CP-945,598 Treatment A, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Peoria, Arizona • Newport Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

NCT00791778
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 3, 2026, 2:58 AM EDT
Recruiting No phase listed Observational

Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.

NCT06507878
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 2 Interventional

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

NCT00000885
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
52
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients

NCT01723943
View directory record Official record
Conditions
Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Psychosocial Effects of Cancer and Its Treatment, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
educational intervention, counseling intervention, psychosocial support for caregiver
Other
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

NCT00027443
View directory record Official record
Conditions
Myocarditis
Interventions
Muromonab-CD3, Cyclosporine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 3, 2026, 2:58 AM EDT
Recruiting Not applicable Interventional

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

NCT06796543
View directory record Official record
Conditions
Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
Interventions
Consolidative radiation therapy (cRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 39 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 2:58 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Rituximab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 2:58 AM EDT
Active, not recruiting Not applicable Interventional

HyaloFAST Trial for Repair of Articular Cartilage in the Knee

NCT02659215
View directory record Official record
Conditions
Defect of Articular Cartilage
Interventions
Hyalofast, Microfracture
Device · Procedure
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
18
States / cities
Tempe, Arizona • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 3, 2026, 2:58 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Safety and Efficacy of TriPollar Device for Treatment of Wrinkles

NCT01858415
View directory record Official record
Conditions
Facial Wrinkles
Interventions
TriPollar
Device
Lead sponsor
Pollogen
Industry
Eligibility
35 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Beverly Hills, California • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 3, 2026, 2:58 AM EDT
Completed No phase listed Observational

Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia

NCT00993135
View directory record Official record
Conditions
Leukemia, Renal Toxicity
Interventions
methotrexate, medical chart review, assessment of therapy complications
Drug · Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 3, 2026, 2:58 AM EDT
Withdrawn Phase 4 Interventional

ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion

NCT00407940
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication
Interventions
Lower extremity Atherectomy and Cryoplasty
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 3, 2026, 2:58 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Nutrition Impact on Tear Film

NCT01561040
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega 3, Vitamins A, D3 and E
Dietary Supplement
Lead sponsor
Eye and Vision Technologies and Research Institute
Network
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
4
States / cities
Conifer, Colorado • Oak Lawn, Illinois • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 3, 2026, 2:58 AM EDT
Completed Early Phase 1 Interventional

ETCare: Safety and Preliminary Efficacy Trial

NCT01688440
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
#1 Respiratory Care Solution
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
2
States / cities
Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 3, 2026, 2:58 AM EDT